NASDAQ: KPRXKiora Pharmaceuticals Inc Stock
$1.67-0.42 (-20.1%)
Updated Jun 1, 2023
KPRX Price
$1.67
Fair Value Price
$9.81
Market Cap
$3.37M
52 Week Low
$1.66
52 Week High
$26.20
P/E
-0.16x
P/B
0.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.63
Operating Cash Flow
-$11M
Beta
0.79
Next Earnings
Jul 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A
KPRX Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KPRX ($1.67) is undervalued by 83.03% relative to our estimate of its Fair Value price of $9.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KPRX ($1.67) is significantly undervalued by 83.03% relative to our estimate of its Fair Value price of $9.81 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KPRX due diligence checks available for Premium users.
Be the first to know about important KPRX news, forecast changes, insider trades & much more!
KPRX News
Valuation
KPRX fair value
Fair Value of KPRX stock based on Discounted Cash Flow (DCF)
Price
$1.67
Fair Value
$9.81
Undervalued by
82.98%
KPRX ($1.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KPRX ($1.67) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
11.46x
Market
52.37x
KPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.33x
Industry
5.14x
KPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
KPRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$16.5M
Liabilities
$6.4M
Debt to equity
0.63
KPRX's short-term assets ($5.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPRX's short-term assets ($5.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$513.2k
KPRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KPRX vs Biotech Stocks
Kiora Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.